Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a …
TM Maher, EM van der Aar, O Van de Steen… - The Lancet …, 2018 - thelancet.com
Background Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function.
People with IPF have increased concentrations of autotaxin in lung tissue and …
People with IPF have increased concentrations of autotaxin in lung tissue and …
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis …
Introduction While current standard of care (SOC) for idiopathic pulmonary fibrosis (IPF)
slows disease progression, prognosis remains poor. Therefore, an unmet need exists for …
slows disease progression, prognosis remains poor. Therefore, an unmet need exists for …
Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials
Importance There is a major need for effective, well-tolerated treatments for idiopathic
pulmonary fibrosis (IPF). Objective To assess the efficacy and safety of the autotaxin inhibitor …
pulmonary fibrosis (IPF). Objective To assess the efficacy and safety of the autotaxin inhibitor …
Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5 …
N Desroy, C Housseman, X Bock, A Joncour… - 2017 - ACS Publications
Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid
(LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many …
(LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many …
Novel autotaxin inhibitor for the treatment of idiopathic pulmonary fibrosis: a clinical candidate discovered using DNA-encoded chemistry
The activity of the secreted phosphodiesterase autotaxin produces the inflammatory
signaling molecule LPA and has been associated with a number of human diseases …
signaling molecule LPA and has been associated with a number of human diseases …
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis
N Hirani, AC MacKinnon, L Nicol, P Ford… - European …, 2021 - Eur Respiratory Soc
Galectin (Gal)-3 is a profibrotic β-galactoside-binding lectin that plays a key role in the
pathogenesis of idiopathic pulmonary fibrosis (IPF) and IPF exacerbations. TD139 is a novel …
pathogenesis of idiopathic pulmonary fibrosis (IPF) and IPF exacerbations. TD139 is a novel …
A phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis
JM Parker, IN Glaspole, LH Lancaster… - American journal of …, 2018 - atsjournals.org
Rationale: IL-13 is a potential therapeutic target for idiopathic pulmonary fibrosis (IPF);
preclinical data suggest a role in tissue fibrosis, and expression is increased in subjects with …
preclinical data suggest a role in tissue fibrosis, and expression is increased in subjects with …
[HTML][HTML] Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is an advancing and fatal lung disease with increasing
incidence and prevalence. Nintedanib and pirfenidone were approved by the FDA for the …
incidence and prevalence. Nintedanib and pirfenidone were approved by the FDA for the …
Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial
G Raghu, B Van Den Blink, MJ Hamblin, AW Brown… - Jama, 2018 - jamanetwork.com
Importance Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with
poor prognosis. Approved therapies do not halt disease progression. Objective To …
poor prognosis. Approved therapies do not halt disease progression. Objective To …
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study
G Raghu, B van den Blink, MJ Hamblin… - The Lancet …, 2019 - thelancet.com
Background Patients with idiopathic pulmonary fibrosis (IPF) treated with PRM-151, a
recombinant human pentraxin 2 protein, in a phase 2 double-blind, randomised controlled …
recombinant human pentraxin 2 protein, in a phase 2 double-blind, randomised controlled …